Business
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO™ Utilizing Halozyme's ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma
- Janssen's DARZALEX FASPRO™ is a subcutaneous co-formulation of DARZALEX® and Halozyme's ENHANZE® technology - - Innovative, fixed-dose formulation
About this update from Halozyme Therapeutics, Inc.
[{"type":"text","content":"- Janssen's DARZALEX FASPRO™ is a subcutaneous co-formulation of DARZALEX® and Halozyme's ENHANZE® technology -\n - Innovative, fixed-dose formulation demonstrates consistent efficacy to intravenous DARZALEX® with lower rate of infusion-related reactions -\n - Can be administered in three to five minutes compared to multi-hour infusions with intravenous DARZALEX® -\n\n\nSAN DIEGO, May 1, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its collaborator Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for DARZALEX FASPRO™ (daratumumab hyaluronidase human- fihj). DARZALEX FASPRO™ is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.\n\"We are delighted that DARZALEX FASPRO™ has been approved in the U.S. making it possible for patients diagnosed with multiple myeloma to receive daratumumab (DARZALEX®) treatment in 3-5 minutes with a subcutaneous injection rather than through a multi-hour intravenous infusion. This can reduce the treatment burden for patients, significantly shortening the time required in the physician clinic, hospital in-patient and out-patient treatment centers,\" said Dr. Helen Torley, president and chief executive officer. \"We are also pleased with the breadth of indications granted to DARZALEX FASPRO™, which includes the majority of the indications granted for the IV DARZALEX® formulation.\"\nDARZALEX FASPRO™ is approved for the treatment of adult patients with multiple myeloma: in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT); in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for ASCT and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy; in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.\nAbout ENHANZE® Technology Halozyme...